成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

SRT1720 HCl

SRT1720 HCl是一種選擇性的SIRT1激活劑，無(wú)細(xì)胞試驗(yàn)中EC50為0.16 μM，對(duì)SIRT2和SIRT3的作用弱230倍以上。SRT1720 還可誘導(dǎo)自噬。

SRT1720 HCl Chemical Structure

SRT1720 HCl Chemical Structure

CAS: 1001645-58-4

規(guī)格 價(jià)格 庫(kù)存 購(gòu)買(mǎi)數(shù)量
10mM (1mL in DMSO) 1960.55 現(xiàn)貨
5mg 1400.82 現(xiàn)貨
50mg 7964.73 現(xiàn)貨
1g 31900 現(xiàn)貨
更大包裝 有超大折扣

400-668-6834

info@selleck.cn
免費(fèi)分裝
免費(fèi)預(yù)溶

常與SRT1720 HCl一起在實(shí)驗(yàn)中被使用的化合物

Selisistat (EX 527)

SRT1720增加Pgrcre/+Rosa26mTmG/+小鼠的子宮內(nèi)膜異位病變，而Selisistat顯著減少子宮內(nèi)膜異位病變的數(shù)量。

Kim TH, et al.J Clin Endocrinol Metab. 2022 Feb 17;107(3):788-800.

Resveratrol

SRT1720增強(qiáng)依托泊苷和長(zhǎng)春新堿誘導(dǎo)的細(xì)胞死亡，而Resveratrol則抑制ES細(xì)胞中的細(xì)胞死亡。

Sonnemann J, et al. J Cancer Res Clin Oncol. 2016 Jan;142(1):17-26.

Quercetin

Quercetin在對(duì)抗D-GalN/LPS對(duì)雄性Wistar大鼠的細(xì)胞毒性作用方面比SRT1720更有效。

Kemelo MK, et al. Eur Rev Med Pharmacol Sci. 2016;20(2):363-71.

Astragaloside IV

SRT1720 HCl和Astragaloside IV在calpain-1敲除中對(duì)血管內(nèi)皮功能障礙(VED)表現(xiàn)出相似的作用。

Zhao F, et al. Front Pharmacol. 2022 Aug 2;13:920977.

MDL-28170

SRT1720 HCl和MDL-28170治療可恢復(fù)人冠狀動(dòng)脈內(nèi)皮細(xì)胞(HCAEC)中線(xiàn)粒體ROS水平的增加和膜電位的降低。

Zhao F, et al. Front Pharmacol. 2022 Aug 2;13:920977.

SRT1720 HCl相關(guān)產(chǎn)品

相關(guān)信號(hào)通路圖

Sirtuin Signaling Pathways

Sirtuin信號(hào)通路圖

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系 實(shí)驗(yàn)類(lèi)型 給藥濃度 孵育時(shí)間 活性描述 文獻(xiàn)信息
MC3T3-E1 Function Assay 10 μM 60 min? attenuates the FGF-2-induced osteoprotegerin mRNA expression 25290095
MC3T3-E1 Function Assay 10 μM 60 min? suppresses the FGF-2-stimulated osteoprotegerin release 25290095
MDA-MB-231 Function Assay 5 μM 16 h induces lysosomal membrane permeabilization 25411356
MDA-MB-231 Function Assay 5 μM 8 h increases the number of acidic vesicular organelles 25411356
Neu Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
HCT116 Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
A459 Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
BT20 Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
HS578T Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
SUM149 Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
MDA-MB-231 Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
SKBR3 Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
T47D Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
MCF-7 Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
MCF10A Growth Inhibition Assay 0-20 μM 24 h reduces cell viability dose dependently 25411356
RAW264.7 Function Assay 1 μM 6 h upregulates the reduced SIRT1 protein or mRNA levels by high glucose 25793995
NRK-49F Function Assay 0–2?μM 36 h enhances STAT3 phosphorylation 26022003
NRK-49F Function Assay 0–2?μM 36 h enhances phosphorylation of EGFR and PDGFRβ? 26022003
NRK-49F Function Assay 0–2?μM 36 h increases expression of α-SMA and fibronectin dose dependently 26022003
SK-N-MC? Function Assay 3 μM 0-24 h activates caspase 3/7 26055805
SK-ES-1 Function Assay 10 μM 0-24 h activates caspase 3/7 26055805
WE-68 Function Assay 20 μM 0-24 h activates caspase 3/7 26055805
SK-N-MC? Apoptosis Assay 0-2.5 μM 24 h induces cell death in dose dependently 26055805
SK-ES-1 Apoptosis Assay 0-10 μM 24 h induces cell death in dose dependently 26055805
WE-68 Apoptosis Assay 0-24 μM 24 h induces cell death in dose dependently 26055805
MC3T3-E1 Function Assay 20 μM 1 h suppresses the TGF-β-induced phosphorylation of p44/p42 MAP kinase or SAPK/JNK 26136978
MC3T3-E1 Function Assay 10 μM? 12 h reduces the VEGF mRNA expression levels stimulated by TGF-β 26136978
MC3T3-E1 Function Assay 10 μM? 1 h reduces the TGF-β-stimulated VEGF release in dose- and time-dependent manner? 26136978
CACs? Function Assay 4?μM 30?min induces acute SIRT1 activation? 26254104
MC3T3-E1 Function Assay 10 μM 60 min? attenuates the FGF-2-induced osteoprotegerin mRNA expression 25290095
MC3T3-E1 Function Assay 10 μM 60 min? suppresses the BMP-4-stimulated VEGF release 24435444
MC3T3-E1 Function Assay 10 μM 60 min? suppresses the PGF2α-stimulated OPG release 24333336
MC3T3-E1 Function Assay 10 μM 60 min? reduces the PGF2α-stimulated phosphorylation of p44/p42 MAP kinase 24333336
MC3T3-E1 Function Assay 10 μM 60 min? attenuates the PGF2α-induced phosphorylation of both MEK1/2 and Raf-1 24333336
RPE Cell Viability Assay 5 μM 1 h attenuates OAβ-induced decrease of cell viability 24036938
9607 Cell Viability Assay 1 μM 36 h increases the cell viability compared with melatonin alone 23726949
9607 Function Assay 1 μM 36 h increases SIRT1 and decreased acetylated-p53 expression 23726949
RPMI.8226 Cell Viability Assay 7/10 μM 24 h decreases viability concentration dependently 21950728
U266 Cell Viability Assay 7/10 μM 24 h decreases viability concentration dependently 21950728
MM.1S Cell Viability Assay 7/10 μM 24 h decreases viability concentration dependently 21950728
KMS12 Cell Viability Assay 7/10 μM 24 h decreases viability concentration dependently 21950728
LR5 Cell Viability Assay 7/10 μM 24 h decreases viability concentration dependently 21950728
MM.1R Cell Viability Assay 7/10 μM 24 h decreases viability concentration dependently 21950728
Ina6 Cell Viability Assay 7/10 μM 24 h decreases viability concentration dependently 21950728
RPMI-8226 Apoptosis Assay 7/10 μM 24 h induces a significant increase in the Annexin V+/PI??apoptosis 21950728
MM.1R? Apoptosis Assay 7/10 μM 24 h induces a significant increase in the Annexin V+/PI??apoptosis 21950728
H411EC3 Function Assay 50/100 nM 6 h increases SIRT1 activity in the presence of TSA, PEPCK activity, mRNA levels of Pck1 and Pgc1α, and elevating glucose production 21212096
hepatocytes Function Assay 10 nM 6 h increases SIRT1 activity in the presence of TSA, PEPCK activity, mRNA levels of Pck1 and Pgc1α, and elevating glucose production 21212096
hepatocytes Function Assay 10 nM 6 h increases Hmgcr?and?Acc?gene expression 21212096
U2OS Function assay 0.10 uM Activation of SIRT1 in human U2OS cells assessed as decrease in p53 deacetylation level at 0.10 uM 18046409
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述 SRT1720 HCl是一種選擇性的SIRT1激活劑，無(wú)細(xì)胞試驗(yàn)中EC50為0.16 μM，對(duì)SIRT2和SIRT3的作用弱230倍以上。SRT1720 還可誘導(dǎo)自噬。
靶點(diǎn)
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
體外研究(In Vitro)
體外研究活性

SRT1720抗最近的乙?；竿滴颯IRT2 (EC1.5為37 μM)和SIRT3 (EC1.5 > 300 μM)的最大激活率達(dá)781%。SRT1720在氨基末端催化區(qū)的變構(gòu)位點(diǎn)結(jié)合到SIRT1酶-肽底物復(fù)合物上，降低乙?；孜锏拿资铣?shù)值。用SRT1720處理一周后，飼喂的葡萄糖水平降低，處理三周后，飼喂的葡萄糖水平進(jìn)一步降低，持續(xù)處理10周。SRT1720對(duì)用無(wú)糖食物喂養(yǎng)的鼠沒(méi)有作用效果，顯示出藥理學(xué)SIRT1的激活不會(huì)產(chǎn)生低血糖。用SRT1720處理4周，明顯降低高胰島素血癥，使升高的胰島素水平恢部分復(fù)正常SRT1720處理腓腸肌，通過(guò)測(cè)定檸檬酸合酶活性發(fā)現(xiàn)線(xiàn)粒體各項(xiàng)能力上升15%。[1]高濃度 SRT1720 (15 μM)誘導(dǎo)正常細(xì)胞活力輕微下降，約10-20%。SRT1720明顯抑制VEGF依賴(lài)的 MM 細(xì)胞遷移。[2]
激酶實(shí)驗(yàn) SIRT1熒光偏振實(shí)驗(yàn)
在SIRT1 FP試驗(yàn)中，使用從p53序列中得到的含20個(gè)氨基酸的肽段 (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly-Lys(MR121或 Tamra)-Glu-Glu-NH2)。肽段N端與生物素相連，C端用熒光標(biāo)記修飾。監(jiān)測(cè)酶活的反應(yīng)是酶活偶聯(lián)反應(yīng)，第一步反應(yīng)為SIRT1催化的脫乙酰反應(yīng)，第二步反應(yīng)為在新暴露的賴(lài)氨酸殘基處進(jìn)行胰蛋白酶催化的分裂。為了突出底物和產(chǎn)物的多種區(qū)別，加入鏈酶親和素，反應(yīng)終止。FP測(cè)試的敏感性可用來(lái)鑒定SRT1720。進(jìn)行熒光偏振反應(yīng)環(huán)境如下：0.5 μM 肽底物, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-醋酸鹽（pH 為8）, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl2, 5 mM DTT, 0.025% BSA, 及0.15 mM煙堿。 反應(yīng)在37oC溫育，加入煙堿終止反應(yīng)，加入胰蛋白酶分裂脫乙酰底物。加入鏈酶親和素在37oC溫育。在650 nm 和680nm 處測(cè)定熒光偏振。
細(xì)胞實(shí)驗(yàn) 細(xì)胞系 人類(lèi)血管內(nèi)皮細(xì)胞(HUVECs)
濃度 5 μM
孵育時(shí)間 2小時(shí)
方法

使用Transwell遷移實(shí)驗(yàn)測(cè)定遷移率。通過(guò)基底膜的毛細(xì)血管樣管結(jié)構(gòu)形成試劑盒檢測(cè)體外血管生成。用于內(nèi)皮血管生成實(shí)驗(yàn)，從Clonetics獲得的人類(lèi)血管內(nèi)皮細(xì)胞（HUVEC），保存在含5% FBS的內(nèi)皮細(xì)胞生長(zhǎng)培養(yǎng)基中。使用臺(tái)盼藍(lán)拒染法測(cè)定HUVEC細(xì)胞活力，觀察到用SRT1720處理的細(xì)胞死亡率小于5%。
實(shí)驗(yàn)圖片 檢測(cè)方法 檢測(cè)指標(biāo) 實(shí)驗(yàn)圖片 PMID
Western blot

感谢您访问我们的网站，您可能还对以下资源感兴趣：

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天
狠狠干天天爽,国产精品天天看天天爽,99色播,十三以下岁女子毛片 国产精品2022不卡在线观看,久久久久青草线蕉亚洲麻豆,91蜜桃国产成人精品区,亚洲精品乱码久久久久久蜜桃图片 欧美综合图区亚洲综合图区69,国产日韩久久久精品影院首页,另类综合视频,国产精品福利久久 久久澳门,h视频在线观看免费网站,69黄在线看片免费视频,精品久久伊人